Latest News for: gsk

Edit

Current Report by Foreign Issuer (Form 6-K) (GSK plc)

Public Technologies 20 Mar 2026
GSK plc published this content on March 20, 2026, and is solely responsible ...
Edit

US FDA Approves GSK's Drug for Liver Disease Related Itching

US News 19 Mar 2026
March ⁠19 (Reuters) - ⁠The U.S. ⁠Food and ​Drug ‌Administration approved ‌GSK's ⁠drug for ⁠severe relentless itching ​caused ​by a type ⁠of ⁠liver... .
Edit

Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC) (Form 6-K) (GSK plc)

Public Technologies 19 Mar 2026
GSK plc ... GSK plc (LSE/NYSE. GSK) today announced that the US Food and Drug Administration (FDA) has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with PBC ... About GSK research in hepatology ... About GSK ... GSK plc.
Edit

Prices of Legacy GSK Antibiotic Surge 50-Fold in China After Rumored Supply Halt

Caixin Online 18 Mar 2026
The price of Zinnat, an old antibiotic originally developed by GSK, has skyrocketed to around 1,500 yuan ($218) a box on ...
Edit

Transaction notification (Form 6-K) (GSK plc)

Public Technologies 18 Mar 2026
GSK plc ... GSK plc (the 'Company') ... GSK plc ... Acquisition of ADS under GSK pension plan ... About GSK. GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Edit

Board Meeting Quarter 4, 2025 (GSK - GlaxoSmithKline Pakistan Ltd)

Public Technologies 18 Mar 2026
). Maich 18, 2026. The General Manager. Pakistan Stock Exchange Limited Stock Exchange Building. Stock Exchange Road Karachi - 74000. Dear Sir,. Subject. Board of Directors Meeting ... T +92 21 111 475 725 ... Tliaiilcing you, ... CC ... GSK - GlaxoSmithKline Pakistan Ltd.
Edit

Transaction in own shares (Form 6-K) (GSK plc)

Public Technologies 16 Mar 2026
GSK plc published this content on March 16, 2026, and is solely responsible ...
Edit

GSK's RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18-49 years at increased risk (Form 6-K) (GSK plc)

Public Technologies 13 Mar 2026
GSK plc ... GSK's RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18-49 years at increased risk ... GSK plc (LSE/NYSE ... Sanjay Gurunathan, GSK Head of Vaccines and Infectious Diseases Research and Development, said ... About GSK.
Edit

GSK’s RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at increased risk (GSK plc)

Public Technologies 13 Mar 2026
GSK plc (LSE/NYSE ... GSK's RSV vaccine was previously approved in the US for the prevention of RSV-related LRTD in adults aged 60 and older, and adults aged 50-59 at increased risk for LRTD caused by RSV ... About GSK's RSV vaccine.
Edit

GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 ...

The Huntsville Item 13 Mar 2026
PHILADELPHIA--(BUSINESS WIRE)--Mar 13, 2026-- ....
Edit

GSK tops Antimicrobial Resistance (AMR) Benchmark Report (GSK plc)

Public Technologies 10 Mar 2026
GSK welcomes independent recognition of our leadership in addressing the urgent global threat of antimicrobial resistance (AMR) in the , issued today ... Tony Wood, Chief Scientific Officer, GSK, said.
Edit

Settlement Administrator Angeion Group Announces Proposed Settlement In DeCostanzo v. GlaxoSmithKline (GSK) Class Action

PR Newswire 10 Mar 2026
What are my rights?If you are a Class member and do nothing, you will be bound by the Settlement and will give up any right to sue GSK in a separate lawsuit related to the legal claims in this lawsuit.
Edit

Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn

The Guardian 10 Mar 2026
UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds. Business live – latest updates ... ....
Edit

GSK and Alfasigma announce agreement on worldwide rights for linerixibat (GSK plc)

Public Technologies 09 Mar 2026
GSK plc (LSE/NYSE. GSK) and Alfasigma S.p.A ... Tony Wood, Chief Scientific Officer, GSK said. "We're proud of the role GSK has played discovering and developing linerixibat to advance treatment in this rare disease with high unmet need ... About GSK.
Edit

GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million

Wall Street Journal 09 Mar 2026
Under the deal, Alfasigma will gain rights to develop, manufacture and commercialize linerixibat ... .

Article Search

tools
×
×
×
×